Statistical and Ontological Analysis of Adverse Events Associated with Monovalent and Combination Vaccines against Hepatitis A and B Diseases

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Xie, Jiangan ^a,b   Zhao, Lili ^c   Zhou, Shangbo ^a   He, Yongqun ^b  

^a CHONGQING UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE; VACCINE;

ADULT; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; MALE; MARKOV CHAIN; MONTE CARLO METHOD;

ADULT; FEMALE; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS C; HUMANS; MALE; MARKOV CHAINS; MONTE CARLO METHOD; VACCINES, COMBINED;

EID: 84989967089     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34318     Document Type: Article

References (63)

1. Henderson, D. A. The eradication of smallpox-an overview of the past, present, and future. Vaccine 29, D7-D9 (2011).
2. Wright, P. F. et al. Strategies for the global eradication of poliomyelitis by the year 2000. New England journal of medicine 325, 1774-1779 (1991).
3. de Quadros, C. A. Global eradication of poliomyelitis and measles: another quiet revolution. Annals of internal medicine 127, 156-158 (1997).
4. Zhou, W. et al. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)-United States, 1991-2001. MMWR Surveill Summ 52, 1-24 (2003).
5. Tatonetti, N. P., Fernald, G. H., Altman, R. B. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. Journal of the American Medical Informatics Association 19, 79-85 (2011).
6. Boobis, A. et al. Drug interactions. Drug Metab Rev 41, 486-527 (2009).
7. Dodd, D. Benefits of combination vaccines: effective vaccination on a simplified schedule. The American journal of managed care 9, S6-12 (2003).
8. FDA. Complete list of vaccines licensed for immunization and distribution in the US. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833
9. Chen, R. T. et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 12, 542-550 (1994).
10. Varricchio, F. et al. Understanding vaccine safety information from the vaccine adverse event reporting system. The Pediatric infectious disease journal 23, 287-294 (2004).
11. Sarntivijai, S. et al. Ontology-Based Combinatorial Comparative Analysis of Adverse Events Associated with Killed and Live Influenza Vaccines. Plos One 7, e49941 (2012).
12. Geier, D. A., Geier, M. R. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 38, 295-301 (2005).
13. Brown, E. G., Wood, L., Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug Safety 20, 109-117 (1999).
14. Brown, E. G. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Drug Safety 26, 145-158 (2003).
15. He, Y. Q. et al. OAE: The Ontology of Adverse Events. J Biomed Semant 5, 29 (2014).
16. Kroger, A. T., Sumaya, C. V., Pickering, L. K., Atkinson, W. L. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Morbidity and Mortality Weekly Report 60, 1-64 (2011).
17. Oldfield, E. C., Keeffe, E. B. The A's and B's of vaccine-preventable hepatitis: improving prevention in high-risk adults. Reviews in gastroenterological disorders 7, 1-21 (2006).
18. Joines, R. W. et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix® ) with corresponding monovalent vaccines (Havrix® and Engerix-B® ) in adults. Vaccine 19, 4710-4719 (2001).
19. Czeschinski, P. A., Binding, N., Witting, U. Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines. Vaccine 18, 1074-1080 (2000).
20. Ambrosch, F. et al. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. Journal of medical virology 44, 452-456 (1994).
21. Ambrosch, F. et al. Simultaneous vaccination against hepatitis A and B: results of a controlled study. Vaccine 10, S142-S145 (1992).
22. Larget, B., Simon, D. L. Markov chain Monte Carlo algorithms for the Bayesian analysis of phylogenetic trees. Molecular Biology and Evolution 16, 750-759 (1999).
23. C. D. C. FDA approval for a combined hepatitis A and B vaccine. MMWR. Morbidity and mortality weekly report 50, 806-807 (2001).
24. Evans, S. J. W., Waller, P. C., Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and Drug Safety 10, 483-486 (2001).
25. Banks, D. et al. Comparing data mining methods on the VAERS database. Pharmacoepidem Dr S 14, 601-609 (2005).
26. Yates, F. Contingency tables involving small numbers and the ? 2 test. Supplement to the Journal of the Royal Statistical Society 1, 217-235 (1934).
27. Sarntivijai, S. et al. Linking MedDRA®-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors. Drug Safety, 1-11 (2016).
28. Xiang, Z., Courtot, M., Brinkman, R. R., Ruttenberg, A., He, Y. OntoFox: web-based support for ontology reuse. BMC research notes 3, 175 (2010).
29. Xiang, Z., Mungall, C., Ruttenberg, A., He, Y. In The 2nd International Conference on Biomedical Ontologies (ICBO). 279-281 (CEUR Workshop Proceedings, 2013).
30. Rubin, D. L., Noy, N. F., Musen, M. A. Protege: a tool for managing and using terminology in radiology applications. Journal of digital imaging 20 Suppl 1, 34-46, doi: 10.1007/s10278-007-9065-0 (2007).
31. FDA. What is a Serious Adverse Event?Available at: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm (Accessed: 9th May 2016).
32. Woo, E. J., Miller, N. B., Ball, R., VAERS, W. G. Adverse events after hepatitis AB combination vaccine. Vaccine 24, 2685-2691 (2006).
33. Nakayama, T., Onoda, K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 25, 570-576 (2007).
34. Martin, A. D., Quinn, K. M., Park, J. H. MCMCpack: Markov chain Monte Carlo in R. Journal of Statistical Software 42 (2011).
35. Pastor, J. et al. Combinations of ascaridole, carvacrol, and caryophyllene oxide against Leishmania. Acta tropica 145, 31-38 (2015).
36. Kohlhapp, F. J. et al. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. Journal for immunotherapy of cancer 3, 18 (2015).
37. FDA. Twinrix vaccine package insert document. Availabe at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094035.htm (Accessed: 9th May 2016).
38. FDA. Havrix vaccine package insert document. Availabe at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110016.htm (Accessed: 9th May 2016).
39. FDA. Engerix-B vaccine package insert document. Available at: http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm110102.htm (Accessed: 9th May 2016).
40. Marcos, E., Zhao, B., He, Y. The Ontology of Vaccine Adverse Events (OVAE) and its usage in representing and analyzing adverse events associated with US-licensed human vaccines. J. Biomedical Semantics 4, 40 (2013).
41. Smith, B. In Invited Papers from the 10th International Conference in Logic Methodology and Philosophy of Science, Oviedo, Spain 19-25 (2003).
42. Ellenberg, S. S., Braun, M. M. Monitoring the safety of vaccines. Drug Safety 25, 145-152 (2002).
43. CDC. Withdrawal of rotavirus vaccine recommendation. MMWR. Morbidity and mortality weekly report 48, 1007 (1999).
44. Moro, P. L., Museru, O. I., Niu, M., Lewis, P., Broder, K. Reports to the Vaccine Adverse Event Reporting System after hepatitis A and hepatitis AB vaccines in pregnant women. American journal of obstetrics and gynecology 210, 561. e561-561. e566 (2014).
45. Li, R. C. et al. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis a pediatric vaccines in toddlers, children and adolescents in china. The Pediatric infectious disease journal 32, e77-e81 (2013).
46. Geier, M., Geier, D. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin Exp Rheumatol 22, 749-755 (2004).
47. Geier, D., Geier, M. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Clinical and experimental rheumatology 20, 767-772 (2002).
48. Geier, D., Geier, M. Hepatitis B vaccination and arthritic adverse reactions: a followup analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Clinical and experimental rheumatology 20, 119 (2002).
49. Geier, M., Geier, D. Arthritic reactions following hepatitis B vaccination: an analysis of the vaccine adverse events reporting system (VAERS) data from 1990 through 1997. Clinical and experimental rheumatology 18, 789 (2000).
50. Alberer, M. et al. Immunogenicity and Safety of Concomitant Administration of a Combined Hepatitis A/B Vaccine and a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults. Journal of travel medicine 22, 105-114 (2015).
51. Hernán, M. A., Jick, S. S., Olek, M. J., Jick, H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis A prospective study. Neurology 63, 838-842 (2004).
52. Karali, Z., Basaranoglu, S. T., Karali, Y., Oral, B., Kilic, S. S. Autoimmunity and Hepatitis A Vaccine in Children. J Invest Allerg Clin 21, 389-393 (2011).
53. Csepregi, A., Treiber, G., Christoph, R., Malfertheiner, P. Acute exacerbation of autoimmune hepatitis induced by Twinrix. World Journal of Gastroenterology 11, 4114-4116 (2005).
54. Stübgen, J. P. Immune-mediated myelitis following hepatitis B vaccination. Autoimmunity reviews 12, 144-149 (2012).
55. Moro, P. L. et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. American journal of obstetrics and gynecology 204, 146. e141-146. e147 (2011).
56. Moro, P. L. et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. American journal of obstetrics and gynecology 205, 473. e471-473. e479 (2011).
57. Zheteyeva, Y. A. et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. American journal of obstetrics and gynecology 207, 59. e51-59. e57 (2012).
58. Chang, S., Ball, R., Braun, M. M. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006. Vaccine 26, 2428-2432 (2008).
59. Cheng, F., Zhao, Z. Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. Journal of the American Medical Informatics Association 21, e278-e286 (2014).
60. Ibrahim, H., Saad, A., Abdo, A., Sharaf Eldin, A. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data. Journal of biomedical informatics 60, 294-308, doi: 10.1016/j.jbi.2016.02.009 (2016).
61. Zhao, X.-M. et al. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput Biol 7, e1002323 (2011).
62. Zaloumis, S. G., Scurrah, K. J., Harrap, S. B., Ellis, J. A., Gurrin, L. C. Non-proportional odds multivariate logistic regression of ordinal family data. Biometrical journal. Biometrische Zeitschrift 57, 286-303, doi: 10.1002/bimj.201300137 (2015).
63. Jackson, D., White, I. R., Carpenter, J. Identifying influential observations in Bayesian models by using Markov chain Monte Carlo. Statistics in medicine 31, 1238-1248, doi: 10.1002/sim.4356 (2012).